Compare AbCellera Biologics Inc (ABCL) vs Novartis AG (NVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Novartis AG — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Novartis AG trades at $155.41 (market cap $298.98B). The key difference: Novartis AG is far larger — about 127.2× AbCellera Biologics Inc's market cap, and Novartis AG pays a 3.02% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NVS | |
|---|---|---|
Market Cap | $2.35B | $298.98B |
Sector | Health | Health |
52-Week High | $8.12 | $168.62 |
52-Week Low | $2.78 | $113.50 |
Enterprise Value | $1.99B | $339.00B |
Dividend Yield | — | 3.02% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
